ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Please cite this article as: LIU J, Son S, Giancaterino M, Narushima M. Difficulty of falling asleep and non-high-density lipoprotein cholesterol level among Canadian older adults: a cross-sectional analysis of the Canadian Longitudinal Study for Aging baseline data. J Geriatr Cardiol 2021; 18(8): 597−608. DOI: 10.11909/j.issn.1671-5411.2021.08.003
Citation: Please cite this article as: LIU J, Son S, Giancaterino M, Narushima M. Difficulty of falling asleep and non-high-density lipoprotein cholesterol level among Canadian older adults: a cross-sectional analysis of the Canadian Longitudinal Study for Aging baseline data. J Geriatr Cardiol 2021; 18(8): 597−608. DOI: 10.11909/j.issn.1671-5411.2021.08.003

Difficulty of falling asleep and non-high-density lipoprotein cholesterol level among Canadian older adults: a cross-sectional analysis of the Canadian Longitudinal Study for Aging baseline data

doi: 10.11909/j.issn.1671-5411.2021.08.003
More Information
  • Corresponding author: jliu@brocku.ca
  • Available Online: 2021-07-27
  • Publish Date: 2021-08-28
  •  OBJECTIVE To examine whether difficulty of falling asleep (DoFA) is associated with non-high-density lipoprotein cholesterol (non-HDL-C) level among Canadian older adults. METHODS 26,954 individuals aged 45–85 years from the baseline data of the Canadian Longitudinal Study for Aging were included in this study. DoFA was categorized into five groups by answer to the question “Over the last month, how often did it take you more than 30 min to fall asleep?” Response options are “Never, < 1 time/week, 1−2 times/week, 3−5 times/week, or 6−7 times/week”. Non-HDL-C, the difference of total cholesterol and HDL-C, were categorized into five categories based on these cut-offs (< 2.6 mmol/L, 2.6−3.7 mmol/L, 3.7−4.8 mmol/L, 4.8−5.7 mmol/L, and ≥ 5.7 mmol/L). Ordinal logistic regression (logit link) continuation ratio models were used to estimate the odds of higher non-HDL-C levels for DoFA status. Adjusted means of non-HDL-C by DoFA status were estimated by general linear models. All analyses were sex separately using analytic weights to ensure generalizability. RESULTS The proportions of DoFA in five categories were 41.6%, 25.7%, 13.6%, 9.4%, 9.7% for females and 52.9%, 24.9%, 10.5%, 6.1%, 5.6% for males, respectively. After adjustment of demographical and other covariates (such as depression, comorbidity, sleeping hour, etc.) compared to those who reported never having DoFA, the ORs (95% CIs) of higher levels of non-HDL-C for those whose DoFA status in < 1 time/week, 1−2 times/week, 3−5 times/week, and 6−7 times/week were 1.12 (1.05−1.21), 1.09 (0.99−1.18), 1.20 (1.09−1.33), 1.29 (1.17−1.43) in females and 1.05 (0.98−1.13), 0.95 (0.87−1.05), 1.21 (1.08−1.37), 0.97 (0.85−1.09) in males, respectively. The adjusted means of non-HDL-C among the five DoFA status were 3.68 mmol/L, 3.73 mmol/L, 3.74 mmol/L, 3.82 mmol/L, 3.84 mmol/L for females and 3.54 mmol/L, 3.58 mmol/L, 3.51 mmol/L, 3.69 mmol/L, 3.54 mmol/L for males, respectively. CONCLUSIONS The results of this study have identified a risk association pattern between DoFA status and non-HDL-C levels in females but not in males. Further research is needed to confirm these findings.
  • loading
  • [1]
    Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006; 98: 1363−1368. doi: 10.1016/j.amjcard.2006.06.032
    [2]
    Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet 2019; 394: 2173−2183. doi: 10.1016/S0140-6736(19)32519-X
    [3]
    Sondermeijer BM, Rana JS, Arsenault BJ, et al. Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. Eur J Clin Invest 2013; 43: 1009−1015. doi: 10.1111/eci.12129
    [4]
    Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53: 316−322. doi: 10.1016/j.jacc.2008.10.024
    [5]
    Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993−2000. doi: 10.1001/jama.2009.1619
    [6]
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486−2497. doi: 10.1001/jama.285.19.2486
    [7]
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499−502. doi: 10.1093/clinchem/18.6.499
    [8]
    Morin CM, LeBlanc M, Bélanger L, et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry 2011; 56: 540−548. doi: 10.1177/070674371105600905
    [9]
    Lucena L, Polesel DN, Poyares D, et al. The association of insomnia and quality of life: Sao Paulo epidemiologic sleep study (EPISONO). Sleep Health 2020; 6: 629−635. doi: 10.1016/j.sleh.2020.03.002
    [10]
    Olfson M, Wall M, Liu SM, et al. Insomnia and impaired quality of life in the United States. J Clin Psychiatry 2018; 79: 17m12020. doi: 10.4088/JCP.17m12020
    [11]
    Garbarino S, Magnavita N, Guglielmi O, et al. Insomnia is associated with road accidents. Further evidence from a study on truck drivers. PLoS One 2017; 12: e0187256. doi: 10.1371/journal.pone.0187256
    [12]
    Bananian S, Lehrman SG, Maguire GP. Cardiovascular consequences of sleep-related breathing disorders. Heart Dis 2002; 4: 296−305. doi: 10.1097/00132580-200209000-00006
    [13]
    Grandner MA, Jackson NJ, Pak VM, et al. Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res 2012; 21: 427−433. doi: 10.1111/j.1365-2869.2011.00990.x
    [14]
    Roux F, D’Ambrosio C, Mohsenin V. Sleep-related breathing disorders and cardiovascular disease. Am J Med 2000; 108: 396−402. doi: 10.1016/S0002-9343(00)00302-8
    [15]
    Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2010; 17: 161−165. doi: 10.1097/MED.0b013e3283373624
    [16]
    Lao XQ, Liu X, Deng HB, et al. Sleep quality, sleep duration, and the risk of coronary heart disease: a prospective cohort study with 60, 586 adults. J Clin Sleep Med 2018; 14: 109−117. doi: 10.5664/jcsm.6894
    [17]
    Liu J, Yuen J, Kang S. Sleep duration, C-reactive protein and risk of incident coronary heart disease--results from the Framingham Offspring Study. Nutr Metab Cardiovasc Dis 2014; 24: 600−605. doi: 10.1016/j.numecd.2013.12.012
    [18]
    Bos MM, Noordam R, van den Berg R, et al. Associations of sleep duration and quality with serum and hepatic lipids: the Netherlands Epidemiology of Obesity study. J Sleep Res 2019; 28: e12776. doi: 10.1111/jsr.12776.
    [19]
    Raina PS, Wolfson C, Kirkland SA, et al. The Canadian longitudinal study on aging (CLSA). Can J Aging 2009; 28: 221−229. doi: 10.1017/S0714980809990055
    [20]
    O’Connell AA. Logistic regrssion models for ordinal response variables. Thousand Oaks, California: SAGE Publications 2006, Inc. https://www.doi.org/10.4135/9781412984812.
    [21]
    CLSA. CLSA Technical Document (version 1.2) Sampling and Computation of Response Rates and Sample Weights for the Tracking (Telephone Interview) Participants and Comprehensive Participants, 2020.
    [22]
    Serdar CC, Cihan M, Yücel D, et al. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb) 2021; 31: 010502. doi: 10.11613/BM.2021.010502
    [23]
    Public Health Agency of Canada. Fast facts from the 2009 Canadian Community Health Survey--Sleep Apnea Rapid Response. In: Canada PHAo, ed., 2010.
    [24]
    Cao Z, Zhang P, He Z, et al. Obstructive sleep apnea combined dyslipidemia render additive effect on increasing atherosclerotic cardiovascular diseases prevalence. Lipids Health Dis 2016; 15: 98. doi: 10.1186/s12944-016-0267-7
    [25]
    Kruisbrink M, Robertson W, Ji C, et al. Association of sleep duration and quality with blood lipids: a systematic review and meta-analysis of prospective studies. BMJ Open 2017; 7: e018585. doi: 10.1136/bmjopen-2017-018585
    [26]
    Zhan Y, Chen R, Yu J. Sleep duration and abnormal serum lipids: the China Health and Nutrition Survey. Sleep Med 2014; 15: 833−839. doi: 10.1016/j.sleep.2014.02.006
    [27]
    Wan Mahmood WA, Draman Yusoff MS, Behan LA, et al. Association between sleep disruption and levels of lipids in Caucasians with type 2 diabetes. Int J Endocrinol 2013; 2013: 341506. doi: 10.1155/2013/341506
    [28]
    Qian Y, Yi H, Zou J, et al. Independent association between sleep fragmentation and dyslipidemia in patients with obstructive sleep apnea. Sci Rep 2016; 6: 26089. doi: 10.1038/srep26089
    [29]
    Petrov ME, Kim Y, Lauderdale D, et al. Longitudinal associations between objective sleep and lipids: the CARDIA study. Sleep 2013; 36: 1587−1595. doi: 10.5665/sleep.3104
    [30]
    Demacker PN, Hijmans AG, Brenninkmeijer BJ, et al. Five methods for determining low-density lipoprotein cholesterol compared. Clin Chem 1984; 30: 1797−1800. doi: 10.1093/clinchem/30.11.1797
    [31]
    Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005; 28: 1916−1921. doi: 10.2337/diacare.28.8.1916
    [32]
    Eliasson M, Janlert U, Jansson JH, et al. Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med 2006; 260: 551−559. doi: 10.1111/j.1365-2796.2006.01730.x
    [33]
    Nepal G, Tuladhar ET, Acharya K, et al. Dyslipidemia and associated cardiovascular risk factors among young Nepalese university students. Cureus 2018; 10: e2089. doi: 10.7759/cureus.2089
    [34]
    Zhao X, Bo L, Zhao H, et al. Cardio-ankle vascular index value in dyslipidemia patients affected by cardiovascular risk factors. Clin Exp Hypertens 2018; 40: 312−317. doi: 10.1080/10641963.2017.1377213
    [35]
    Sliwa K, Lyons JG, Carrington MJ, et al. Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. Cardiovasc J Afr 2012; 23: 389−395. doi: 10.5830/CVJA-2012-036
    [36]
    Liu J, Son S, Giancaterino M, et al. Non-HDL cholesterol level and depression among Canadian elderly--a cross-sectional analysis of the baseline data from the CLSA. FACETS 2020; 5: 1006−1018. doi: 10.1139/facets-2020-0039
    [37]
    Liu J, Son S, Mcintyre J, et al. Depression and cardiovascular diseases among Canadian older adults: a cross-sectional analysis of baseline data from the CLSA Comprehensive Cohort. J Geriatr Cardiol 2019; 16: 847−854. doi: 10.11909/j.issn.1671-5411.2019.12.001
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Article Metrics

    Article views (201) PDF downloads(17) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return